Why the study?
Cardiovascular diseases during pregnancy are the most common causes of pregnancy-associated mortality.
Provides a summary of the 2018 ESC guidelines for managing cardiovascular diseases during pregnancy, highlighting risk stratification and multidisciplinary care.
Supports multidisciplinary prepregnancy counseling for mWHO II-IV cardiac patients; leaves open prospective validation of delivery outcomes.
Cardiovascular diseases during pregnancy are the most common causes of pregnancy-associated mortality.Vaginal delivery is the preferred mode of birth in the majority of pregnancies.It is recommended that patients with modified World Health Organization (mWHO) class IV risk are counselled against pregnancy.Patients carrying mWHO II-III, III, and class IV risks should undergo prepregnancy counselling by a multidisciplinary pregnancy heart team to determine a delivery plan and define postpartum care.Specific medications should not be principally withheld in pregnancy but the risk-benefit ratio should be carefully evaluated prior to administration.Beta blockers are recommended during and after pregnancy for congenital long QT syndrome and catecholaminergic polymorphic ventricular tachycardia.Low molecular weight heparin is the ideal substance for prophylaxis and treatment of venous thromboembolism in pregnancy under weekly monitoring of anti-factor Xa activity.
No takes yet. Share an insight, caveat, or question.
Iréne Lang (2019) conducted a review in Cardiovascular diseases during pregnancy. 2018 ESC guidelines was evaluated. The 2018 ESC guidelines introduce the pregnancy heart team, recommend the mWHO classification for maternal risk, and provide updated guidance on contraception, assisted reproduction, and PPCM treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: